akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Friday, June 17, 2016

Company News: Curetis Reports Results of the Annual Shareholder Meeting Held on June 16, 2016

- Dr. Prabhavathi Fernandes elected as member of the Supervisory Board

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 16, 2016.

The shareholders approved all items on the agenda of the AGM, including the election of Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC, USA) as a member of Curetis´ Supervisory Board for a three-year term until 2019. Prabhavathi Fernandes has profound knowledge in infectious diseases and antibiotics as well as experience in successfully founding, building up and leading several biotech companies and taking one public on Nasdaq raising more than half a billion dollars.

Wednesday, June 15, 2016

Company News: Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge

- Interim data from prospective multicenter evaluation show 98% concordance with conventional microbiology

- Unyvero results on average available 24 hours earlier than in conventional microbiology, enabling rapid decision on appropriate antibiotic therapy

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the broad commercial roll-out of its new Unyvero BCU Blood Culture Application Cartridge, which was introduced during ECCMID in April 2016. The roll-out has been initiated in Europe, the Middle East and Asia via Curetis’ internal sales force and the company’s distribution partner network.

The market launch is supported by excellent interim data from an external, prospective, multicenter evaluation comparing the performance of the BCU Application Cartridge against the performance of conventional microbiology work-up of positive blood cultures that is ongoing at three European hospitals.